The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | TRANSCEND-CLL-004 study update: safety and efficacy of liso-cel in R/R CLL
Tanya Siddiqi, MD, City of Hope, Duarte, CA, summarizes outcomes of the Phase I/II TRANSCEND-CLL-004 study (NCT03331198), which is investigating the safety and efficacy of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This study met its primary endpoint, and Dr Siddiqi talks on the clinical benefit of this CAR-T product in this patient population. To conclude, Dr Siddiqi highlights the curative potential of this therapy and comments on the possibility of using CAR-T cells earlier in the treatment of CLL or in combination with other agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
